Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia

[1]  J. Rowe.  Important milestones in acute leukemia in 2013. , 2013, Best practice & research. Clinical haematology.

[2]  A. Krämer,et al.  Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Greil,et al.  Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). , 2013, Blood.

[4]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[5]  J. Gerss,et al.  Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia — A Randomised SAL Pilot Study , 2012, PloS one.

[6]  W. Hiddemann,et al.  Factors Influencing Complete Remission (CR) Rate in Patients ≥ 60 Years with Acute Myeloid Leukemia (AML): Report From the German AML Intergroup Study , 2012 .

[7]  M. Minden,et al.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  U. Dührsen,et al.  Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[10]  R. Arceci.  Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia , 2012 .

[11]  J. Scandura,et al.  Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. , 2011, Blood.

[12]  R. Arceci,et al.  Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia , 2011 .

[13]  C. Müller-Tidow,et al.  DNA methylation as a pathogenic event and as a therapeutic target in AML. , 2011, Cancer treatment reviews.

[14]  W. Hiddemann,et al.  Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes , 2010, The Lancet.

[15]  G. Ehninger,et al.  A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. , 2010, Blood.

[16]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[18]  Sören Lehmann,et al.  Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.

[19]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[20]  W. Hiddemann,et al.  Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Galmarini,et al.  Problems Related to Resistance to Cytarabine in Acute Myeloid Leukemia , 2004, Leukemia & lymphoma.

[22]  V. Avramis,et al.  Pharmacodynamic and DNA methylation studies of high-dose 1-β-d-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia , 2004, Cancer Chemotherapy and Pharmacology.

[23]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  T. Chou,et al.  Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine. , 1991, Molecular pharmacology.

[25]  G. Neil,et al.  Combination chemotherapy of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine. , 1976, Cancer Research.